Business Segments · D&A
Medical — D&A
Becton, Dickinson and Company Medical — D&A remained flat by 0.0% to $348.25M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 14.6%, from $304.00M to $348.25M. Over 4 years (FY 2021 to FY 2025), Medical — D&A shows an upward trend with a 5.1% CAGR.
Analysis
How to read this metric
Increasing levels often correlate with higher historical capital investment, while sudden spikes may indicate asset impairment or changes in depreciation schedules.
Detailed definition
This metric reflects the systematic allocation of the cost of tangible and intangible assets over their useful lives wit...
Peer comparison
Standard non-cash expense metric used across all capital-intensive industries to reconcile accounting profit to cash flow.
Metric ID:
bdx_segment_medical_depreciation_and_amortizationHistorical Data
5 years
| FY'21 | FY'22 | FY'23 | FY'24 | FY'25 | |
|---|---|---|---|---|---|
| Value | $1.14B | $1.14B | $1.20B | $1.22B | $1.39B |
| YoY Change | — | +0.4% | +4.8% | +1.4% | +14.6% |
Range$1.14B – $1.39B
CAGR+5.1%
Avg YoY Growth+5.3%
Median YoY Growth+3.1%
Current Streak4+ years growth
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Becton, Dickinson and Company's medical — d&a?
- Becton, Dickinson and Company (BDX) reported medical — d&a of $348.25M in Q3 2025.
- How has Becton, Dickinson and Company's medical — d&a changed year-over-year?
- Becton, Dickinson and Company's medical — d&a increased by 14.6% year-over-year, from $304.00M to $348.25M.
- What is the long-term trend for Becton, Dickinson and Company's medical — d&a?
- Over 4 years (2021 to 2025), Becton, Dickinson and Company's medical — d&a has grown at a 5.1% compound annual growth rate (CAGR), from $1.14B to $1.39B.
- What does medical — d&a mean?
- The non-cash expense representing the aging and usage of the medical segment's physical and intangible assets.